High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review.

Abstract

A dose-response relationship has been demonstrated for metastatic human breast cancer. This increased response using moderately increased doses is generally not translated into an improved survival. The use of high-dose therapy to selected patients with metastases/recurrence responding to conventional doses of polychemotherapy may lead to an improved survival tail. Conventional doses of polychemotherapy in the adjuvant setting will reduce the relative mortality by around 25% 10 years after primary diagnosis. The use of high-dose therapy supported by autologous bone marrow stem cells may be markedly more effective in the adjuvant setting, especially to high-risk patients, compared with standard polychemotherapy. Several randomized studies are being planned or have already started in order to answer different aspects of this issue.

• Authors: J Bergh
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 34 Issue 5 Pg. 669-74 ( 1995) ISSN: 0284-186X [Print] England
• PMID: 7546837 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (administration & dosage, therapeutic use)
• Bone Marrow Transplantation
• Breast Neoplasms (pathology, surgery, therapy)
• Chemotherapy, Adjuvant
• Combined Modality Therapy
• Female
• Humans
• Stem Cell Transplantation
• Time Factors